MyFinsight
Home
Blog
About
Contact
Download
Download image
Vendor advances, gross
$3,271K
Cash and cash
equivalents
$4,491K
Vendor advances, net
$845K
Prepaid expenses and
other current assets
$51K
Deferred offering costs
$1,091K
Intangible assets, net
$62K
Less accumulated
amortization
$2,426K
Total current assets
$5,387K
Total other assets
$1,153K
Total assets
$6,540K
Total liabilities and
shareholders equity
$6,540K
Total shareholders
equity
$6,341K
Total current
liabilities
$199K
Accumulated deficit
-$14,262K
Additional paid-in capital
$20,582K
Accounts payable and
accrued expenses
$199K
Common stock, par value
0.001, 100,000,000...
$21K
Back
Back
Balance Sheet
source: myfinsight.com
Kairos Pharma, LTD. (KAPA)
Kairos Pharma, LTD. (KAPA)